Ripretinib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. MedsAcross supplies Ripretinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Source: US FDA prescribing information
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
Source: US FDA prescribing information
Recommended Dosage: 150 mg orally once daily with or without food. Recommended Dosage The recommended dosage of QINLOCK is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity. Instruct patients to swallow tablets whole. Advise patients to take QINLOCK at the same time each day. Advise patients to take a missed dose if less than 8 hours have passed since the missed scheduled dose. Advise patients not to take an additional dose if vomiting occurs after taking QINLOCK and to continue with their next scheduled dose.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Palmar-Plantar Erythrodysesthesia Syndrome: Based on severity, withhold QINLOCK and resume at same or reduced dose. New Primary Cutaneous Malignancies: Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment. Hypertension: Do not initiate QINLOCK in patients with uncontrolled hypertension and monitor blood pressure during treatment. Based on severity, withhold QINLOCK and then resume at same or reduced dose or permanently discontinue. Cardiac Dysfunction: Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction. Risk of Impaired Wound Healing: Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed elsewhere in the labeling: Palmar-Plantar Erythrodysesthesia Syndrome New Primary Cutaneous Malignancies Hypertension Cardiac Dysfunction Photosensitivity The most common adverse reactions (≥20%) were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting. The most common Grade 3 or 4 laboratory abnormalities (≥4%) were increased lipase and decreased phosphate.
Source: US FDA prescribing information
Strong CYP3A Inhibitors: Monitor more frequently for adverse reactions. Strong CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. Moderate CYP3A Inducers: Avoid concomitant use of moderate CYP3A inducers. If a moderate CYP inducer cannot be avoided, increase ripretinib dose frequency to twice daily.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C (59°F to 86°F). Store in the original container with the desiccant to protect from moisture and light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Ripretinib, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Qinlock 50 mg tabletOral | Deciphera Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ripretinib in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Ripretinib and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ripretinib, including Qinlock.
Yes. The US FDA first approved Ripretinib on 15 May 2020, according to Drugs@FDA.
Yes. Ripretinib has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Ripretinib is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ripretinib is classified under ATC code L01 (Cancer medicines (antineoplastics)).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.